ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.
Zydus delivered a record-breaking FY26 with 17% revenue growth and peak EBITDA margins of 31.2%, significantly exceeding internal expectations.
Zydus Lifesciences reported strong FY26 performance with 16% YoY revenue growth and EBITDA margins expanding to 31.2%. Strategic focus remains on US specialty/rare diseases and domestic chronic therapy leadership.